LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Cerrado

SectorSanidad

8.73 0.92

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.45

Máximo

8.75

Métricas clave
By Trading Economics
Ingresos	-8M -74M
Ventas	5.5M 21M
Margen de beneficios	-357.186
Empleados	192
EBITDA	-1.3M -74M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+248.44% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-121M 727M
Apertura anterior	7.81
Cierre anterior	8.73

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 feb 2026, 23:53 UTC

Acciones populares

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 feb 2026, 17:55 UTC

Acciones populares

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 feb 2026, 23:46 UTC

Adquisiciones, fusiones, absorciones

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Adquisiciones, fusiones, absorciones

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Ganancias

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Ganancias

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Ganancias

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Adquisiciones, fusiones, absorciones

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Charlas de Mercado

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Charlas de Mercado

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Charlas de Mercado

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Ganancias

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 19:38 UTC

Ganancias

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 feb 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 feb 2026, 18:45 UTC

Ganancias

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 feb 2026, 18:45 UTC

Charlas de Mercado

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 feb 2026, 17:07 UTC

Ganancias

Pemex Cuts 4Q Loss As Operating Results Improve

27 feb 2026, 17:00 UTC

Charlas de Mercado

Corn Rides Oil Momentum Higher -- Market Talk

27 feb 2026, 16:31 UTC

Charlas de Mercado

Canadian Economy Shows Resilience -- Market Talk

27 feb 2026, 16:17 UTC

Charlas de Mercado

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 feb 2026, 15:49 UTC

Ganancias

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

248.44% repunte

Estimación a 12 Meses

Media 30.14 USD 248.44%

Máximo 40 USD

Mínimo 20 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.